The Italian biotech company Evvivax has developed an anti-Covid vaccine for cats based on electroporation technology, which is also used in the human vaccine developed by Takis Biotech of Castel Romano. In the first phase 1 study, the drug was shown to trigger a strong antibody response after the first administration, and did not cause any adverse reactions in cats.
A kind Coronavirus disease vaccine Design for me Cat -But will also be destined to be given to others animal -Gave very positive results at first Phase 1 study.The vaccine is made byEvvivax, Italy And American Applied DNA Science, Indeed after the first dose is triggered Mass production of neutralizing antibodies In all Cats Involved, the result also Well toleratedBut not sure Adverse reactions.By the end of April, with Second dose. Scientists will continue to monitor vaccinated cats to determine its duration.immunity, A precious fact, which is still not clear even to me Covid vaccine for humans (According to AIFA, the expected protection should be 9-12 months).
The drug for cats is called LinearDNA™COVID-19The technology is based on the same technology as the human anti-Covid vaccine developed by Castel Romano biotechnology company Takis Biotech, and its CEO Dr. Luigi Aurisicchio is not surprisingly also responsible for Evvivax. Both vaccines rely on “Electroporation“,or Electric pulse Sent after vaccination (via Intramuscular injection) To promote the entry of active ingredients into the cell and trigger immune response Against this Protein S Ø spike of Coronavirus SARS-CoV-2, Is the pathogen responsible for COVID-19.
Dr. Aurisicchio told ANSA: “In all the treated animals, we have observed the formation of neutralizing antibodies after a single administration of linear synthetic DNA. By the end of April, we will be able to see the results of the second injection.” “This It is a very positive result that confirms the technology behind the vaccine. The scientist added that the molecular design is the same as that developed by Takis for human vaccines and is being tested with another Italian company, Rottapharm Biotech. He emphasized that LinearDNA ™The preliminary results of COVID-19 represent “the first real proof of principle that a genetic vaccine against SARS-CoV-2 based on DNA electroporation technology can stimulate an immune response. “
Test on cats In the U.S. It was performed at Cornell University Animal Health Diagnostic Center, and antibody titers were evaluated 20 days after vaccination. In healthy cats, the candidate vaccines administered by electroporation are well tolerated and have no adverse reactions. The preliminary results of antibody production reaching this level are very encouraging and support the continued development of candidate vaccines. Press release Veterinary oncologist Joseph Impellizeri participated in the study.As explained by James A. Hayward, CEO and President of Applied DNA Sciences, it is expected Remember The concentration of neutralizing antibody will be 3-4 times higher than that observed after the first dose.
In general, cats and cats, such as tigers, lions and snow leopards in zoos, are particularly vulnerable to SARS-CoV-2 coronavirus infection, as shown by the infections of tigers, lions and snow leopards in zoos. Therefore, the development of vaccines like LinearDNA™ Important to prevent these animals from becoming tank each New variant Potentially able to jump to humans. For example, a recent survey found that the English variant B.1.17 was also found in dogs and cats.There is currently no evidence pet Infected people can spread the virus to humans (infected people are humans). Experts also pointed out that there are still too few tests on cats and dogs to truly understand Infection rate.
Candidate vaccines will also be Visoni, Animals more severely infected by SARS-CoV-2, farm. In Denmark, the authorities have eliminated more than 17 million minks (all minks in the farm) because the coronavirus has been transmitted from humans to animals and returned to farmers to some extent. Antibody resistance. Russia recently approved Karnivak-Kov, the first Covid vaccine for animals, which can produce antibodies in 100% of cases. In addition to cats and dogs, it will also be used to protect farm animals.